Cargando…
Analytical validation of a novel multi-analyte plasma test for lung nodule characterization
BACKGROUND: In the National Lung Screening Trial, 96.4% of nodules had benign etiology. To avoid unnecessary actions and exposure to harm, individuals with benign disease must be identified. We describe herein the analytical validation of a multi-analyte immunoassay for characterizing the risk that...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486005/ https://www.ncbi.nlm.nih.gov/pubmed/32923944 http://dx.doi.org/10.15761/brr.1000123 |
_version_ | 1783581259597873152 |
---|---|
author | Trivedi, Neil N Brown, James K Rubenstein, Tess Rostykus, Abigail D Fish, Amanda L Yu, Heng Carbonell, Luis Juang, Alice Kamer, Sandy Patel, Bhavin Sidhu, Manpreet Vuong, Doris Wang, Shan Beggs, Mike Wu, Alan HB Arjomandi, Mehrdad |
author_facet | Trivedi, Neil N Brown, James K Rubenstein, Tess Rostykus, Abigail D Fish, Amanda L Yu, Heng Carbonell, Luis Juang, Alice Kamer, Sandy Patel, Bhavin Sidhu, Manpreet Vuong, Doris Wang, Shan Beggs, Mike Wu, Alan HB Arjomandi, Mehrdad |
author_sort | Trivedi, Neil N |
collection | PubMed |
description | BACKGROUND: In the National Lung Screening Trial, 96.4% of nodules had benign etiology. To avoid unnecessary actions and exposure to harm, individuals with benign disease must be identified. We describe herein the analytical validation of a multi-analyte immunoassay for characterizing the risk that a lung nodule found on CT is malignant. Those at lower risk may be considered for serial surveillance to avoid unnecessary and potentially harmful procedures. While those nodules characterized at higher risk may be appropriate for more aggressive actions. OBJECTIVE: To validate the analytical performance of multiplexed plasma protein assays used in a novel test for lung nodule characterization. METHODS: A multiplexed immunoassay panel for the measurement of plasma proteins in current smokers who present with a lung nodule on CT scan was evaluated in a clinical testing laboratory. Assay analytical sensitivity, reproducibility, precision, and recovery of Epidermal Growth Factor Receptor (EGFR), Prosurfactant protein B (ProSB), and Tissue Inhibitor of Metalloproteinases 1 (TIMP1) from human EDTA plasma samples were evaluated across multiple runs, lots, and technicians. Interfering substances and sample pre-analytical storage conditions were evaluated for their effect on analyte recovery. The lung nodule risk score reproducibility was assessed across multiple lots. RESULTS: The assay sensitivities were 0.10 ng/mL EGFR, 0.02 ng/mL ProSB, and 0.29 ng/mL TIMP1 with over three orders of magnitude in the assay dynamic ranges. The assays and analytes are robust to pre-analytical sample handling and the plasma can be stored for up to 4 days at 4°C either when freshy collected or thawed after long-term storage at −80°C. Total imprecision after 20 days of testing remained under 9% for all three assays. Risk score variability remained within a ± 10% risk score range. CONCLUSIONS: The three protein assays comprising the multi-analyte plasma test for lung nodule characterization performed quite acceptably in a clinical laboratory. |
format | Online Article Text |
id | pubmed-7486005 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
record_format | MEDLINE/PubMed |
spelling | pubmed-74860052020-09-11 Analytical validation of a novel multi-analyte plasma test for lung nodule characterization Trivedi, Neil N Brown, James K Rubenstein, Tess Rostykus, Abigail D Fish, Amanda L Yu, Heng Carbonell, Luis Juang, Alice Kamer, Sandy Patel, Bhavin Sidhu, Manpreet Vuong, Doris Wang, Shan Beggs, Mike Wu, Alan HB Arjomandi, Mehrdad Biomed Res Rev Article BACKGROUND: In the National Lung Screening Trial, 96.4% of nodules had benign etiology. To avoid unnecessary actions and exposure to harm, individuals with benign disease must be identified. We describe herein the analytical validation of a multi-analyte immunoassay for characterizing the risk that a lung nodule found on CT is malignant. Those at lower risk may be considered for serial surveillance to avoid unnecessary and potentially harmful procedures. While those nodules characterized at higher risk may be appropriate for more aggressive actions. OBJECTIVE: To validate the analytical performance of multiplexed plasma protein assays used in a novel test for lung nodule characterization. METHODS: A multiplexed immunoassay panel for the measurement of plasma proteins in current smokers who present with a lung nodule on CT scan was evaluated in a clinical testing laboratory. Assay analytical sensitivity, reproducibility, precision, and recovery of Epidermal Growth Factor Receptor (EGFR), Prosurfactant protein B (ProSB), and Tissue Inhibitor of Metalloproteinases 1 (TIMP1) from human EDTA plasma samples were evaluated across multiple runs, lots, and technicians. Interfering substances and sample pre-analytical storage conditions were evaluated for their effect on analyte recovery. The lung nodule risk score reproducibility was assessed across multiple lots. RESULTS: The assay sensitivities were 0.10 ng/mL EGFR, 0.02 ng/mL ProSB, and 0.29 ng/mL TIMP1 with over three orders of magnitude in the assay dynamic ranges. The assays and analytes are robust to pre-analytical sample handling and the plasma can be stored for up to 4 days at 4°C either when freshy collected or thawed after long-term storage at −80°C. Total imprecision after 20 days of testing remained under 9% for all three assays. Risk score variability remained within a ± 10% risk score range. CONCLUSIONS: The three protein assays comprising the multi-analyte plasma test for lung nodule characterization performed quite acceptably in a clinical laboratory. 2018-11-23 2018-12 /pmc/articles/PMC7486005/ /pubmed/32923944 http://dx.doi.org/10.15761/brr.1000123 Text en This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Trivedi, Neil N Brown, James K Rubenstein, Tess Rostykus, Abigail D Fish, Amanda L Yu, Heng Carbonell, Luis Juang, Alice Kamer, Sandy Patel, Bhavin Sidhu, Manpreet Vuong, Doris Wang, Shan Beggs, Mike Wu, Alan HB Arjomandi, Mehrdad Analytical validation of a novel multi-analyte plasma test for lung nodule characterization |
title | Analytical validation of a novel multi-analyte plasma test for lung nodule characterization |
title_full | Analytical validation of a novel multi-analyte plasma test for lung nodule characterization |
title_fullStr | Analytical validation of a novel multi-analyte plasma test for lung nodule characterization |
title_full_unstemmed | Analytical validation of a novel multi-analyte plasma test for lung nodule characterization |
title_short | Analytical validation of a novel multi-analyte plasma test for lung nodule characterization |
title_sort | analytical validation of a novel multi-analyte plasma test for lung nodule characterization |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7486005/ https://www.ncbi.nlm.nih.gov/pubmed/32923944 http://dx.doi.org/10.15761/brr.1000123 |
work_keys_str_mv | AT trivedineiln analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT brownjamesk analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT rubensteintess analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT rostykusabigaild analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT fishamandal analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT yuheng analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT carbonellluis analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT juangalice analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT kamersandy analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT patelbhavin analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT sidhumanpreet analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT vuongdoris analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT wangshan analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT beggsmike analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT wualanhb analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization AT arjomandimehrdad analyticalvalidationofanovelmultianalyteplasmatestforlungnodulecharacterization |